1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Ascenta Therapeutics, Inc. - Product Pipeline Review - 2013

Ascenta Therapeutics, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 30 pages

Ascenta Therapeutics, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Ascenta Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Ascenta Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ascenta Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ascenta Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Ascenta Therapeutics, Inc. - Brief Ascenta Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ascenta Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ascenta Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ascenta Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Ascenta Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ascenta Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ascenta Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ascenta Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ascenta Therapeutics, Inc. and identify potential opportunities in those areas.

Table Of Contents

Ascenta Therapeutics, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Ascenta Therapeutics, Inc. Snapshot 4
Ascenta Therapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
Ascenta Therapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Ascenta Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Out-Licensed Products/Combination Treatment Modalities 10
Partnered Products/Combination Treatment Modalities 11
Ascenta Therapeutics, Inc. - Pipeline Products Glance 12
Ascenta Therapeutics, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Ascenta Therapeutics, Inc. - Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Ascenta Therapeutics, Inc. - Drug Profiles 15
AT-101 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
AT-406 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
MI-63 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Ascenta Therapeutics, Inc. - Pipeline Analysis 22
Ascenta Therapeutics, Inc. - Pipeline Products by Therapeutic Class 22
Ascenta Therapeutics, Inc. - Pipeline Products by Route of Administration 23
Ascenta Therapeutics, Inc. - Pipeline Products By Mechanism of Action 24
Ascenta Therapeutics, Inc. - Recent Pipeline Updates 26
Ascenta Therapeutics, Inc. - Dormant Projects 27
Ascenta Therapeutics, Inc. - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables


Ascenta Therapeutics, Inc., Key Information 4
Ascenta Therapeutics, Inc., Key Facts 4
Ascenta Therapeutics, Inc. - Pipeline by Indication, 2013 7
Ascenta Therapeutics, Inc. - Pipeline by Stage of Development, 2013 8
Ascenta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 9
Ascenta Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2013 10
Ascenta Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2013 11
Ascenta Therapeutics, Inc. - Phase II, 2013 12
Ascenta Therapeutics, Inc. - Phase I, 2013 13
Ascenta Therapeutics, Inc. - Pre-Clinical, 2013 14
Ascenta Therapeutics, Inc. - Pipeline By Therapeutic Class, 2013 22
Ascenta Therapeutics, Inc. - Pipeline By Route of Administration, 2013 23
Ascenta Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2013 25
Ascenta Therapeutics, Inc. - Recent Pipeline Updates, 2013 26
Ascenta Therapeutics, Inc. - Dormant Developmental Projects,2013 27

List of Figures


Ascenta Therapeutics, Inc. - Pipeline by Indication, 2013 6
Ascenta Therapeutics, Inc. - Pipeline by Stage of Development, 2013 8
Ascenta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 9
Ascenta Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.